{"url_path":"/sec/biaf/8-k/2026-07-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-034183-index.html","accession_number":"0001493152-26-034183","cik":"0001712762","ticker":"BIAF","issuer_name":"bioAffinity Technologies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1712762/0001493152-26-034183-index.html","primary_entity_key":"0001712762","primary_entity_name":"bioAffinity Technologies, Inc."},"word_count":80,"has_tables":true,"body_markdown":"**Item\n8.01. Other Events.**\n\n \n\nOn\nJuly 22, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing\na collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and commercialization of the Company’s\nnext-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic\nobstructive pulmonary disease (COPD).\n\n \n\nA\ncopy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference."}